Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Torudokimab - Zura Bio

Drug Profile

Torudokimab - Zura Bio

Alternative Names: IL-33 antibody - Zura Bio; LY-3375880; ZB-880

Latest Information Update: 20 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Zura Bio
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • Discontinued Atopic dermatitis

Most Recent Events

  • 14 Aug 2023 Zura Bio plans a phase II trial for Asthma in 2024
  • 19 May 2023 Discontinued - Phase-II for Atopic dermatitis in France, Czech Republic, Canada, Austria, Argentina, USA, Czech Republic, Germany, Hungary, Italy, Spain, Puerto Rico, Mexico, Japan (SC)
  • 19 May 2023 Zura Bio plans to gain US FDA regulatory feedback and alignment for torudokimab on phase II/III designs for Asthma in the US in H2 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top